Rohit Vanjani

Revance Therapeutics Inc (NASDAQ: RVNC) announced interim Phase 2a results for RT002 in treating Plantar Fasciitis, which showed improvement over placebo for pain at eight weeks, the primary endpoint of the study. However, the study didn't meet statistical significance. The Analyst...

Rohit Vanjani of Oppenheimer rates stocks in the biotechnology sector and is one of the top 25 analysts rated on TipRanks. Yesterday, Vanjani made two news ratings for Opko Health Inc. (NYSE: OPK) and OvaScience Inc (NASDAQ: OVAS). Vanjani maintained a Perform rating on Opko Health Inc though...

In a report published Wednesday, Oppenheimer analyst Rohit Vanjani discussed a recent investor meeting with OvaScience Inc (NASDAQ: OVAS)'s management team, including the company's Chief Executive Officer Dr. Michelle Dipp. OvaScience noted that both patient and physician inquiries have moved...

Oppenheimer commented on OvaScience Inc (NASDAQ: OVAS) Thursday and maintained an Outperform rating with a $60 price target. Analyst Rohit Vanjani felt that the recent 40 percent decline in the stock was "primarily due to a misunderstanding from the data presentation at the Society for...

OvaScience Inc (NASDAQ: OVAS) shares were off nearly 6 percent Friday following a company conference call with analysts concerning its fertility treatment. The Cambridge, Massachusetts-based company changed hands recently at $44.49, down $3.80. The shares have gained more than 180 percent in...

Opko Health Inc. (NYSE: OPK) investor expectations are too high, although the company is on track with growth plans, an analyst said Tuesday. Oppenheimer's Rohit Vanjani downgraded the drug and diagnostics company to Market Perform, from Outperform, and cut his 2015 revenue estimate more...

In a report published Wednesday, Oppenheimer analyst Rohit Vanjani initiated coverage on ANI Pharmaceuticals (NASDAQ: ANIP) with an Outperform rating and $29.00 price target. According to the report, the shares of ANIP are up roughly ~230 percent since its merger with BioSante, largely on the...

Oppenheimer analyst Rohit Vanjani Upgraded Lannett (NYSE: LCI) from Perform to Outperform and set a $29 PT following Impax Labs price boost on generic digoxin. Vanjani downgraded Lannett two days from Outperform to Perform and removed his $20 PT a mere two days ago. In Wednesday's note, the...

In a report published Wednesday, Oppenheimer analyst Rohit Vanjani downgraded the rating on Lannett Company (NYSE: LCI) from Outperform to Perform, and removed the $20.00 price target. In the report, Oppenheimer noted, “We are downgrading shares of LCI to Perform and removing our $20 PT, due...

In a report published Wednesday, Oppenheimer analyst Rohit Vanjani initiated coverage on Insys Therapeutics (NASDAQ: INSY) with an Outperform rating and $23.00 price target. In the report, Oppenheimer noted, “We are initiating coverage of Insys Therapeutics with an Outperform rating and $23...